We are pleased to present MedTech company NeoDynamics’ Board Member Matt E. Colpoys, in an interview with HC Andersen Capital. Matt discusses the challenges and success factors for smaller companies entering the US market. Matt started his career at Genentech, as the company was beginning its exciting journey. He has since built on that experience, which has led him to a diverse and successful career. The interview takes place at a time when NeoDynamics is preparing the launch of its novel biopsy system NeoNavia on the US market.
The interview can be accessed on the following link: https://youtu.be/IyefG5mr93s
For further information, please contact:
CEO Anna Eriksrud, phone +46 708 444 966 or e-mail firstname.lastname@example.org
CFO Aaron Wong, phone +46 735 972 011 or e-mail email@example.com
NeoDynamics AB (publ) is a Swedish Medical Technology Company dedicated to advancing diagnosis and care of breast cancer. The company’s first product NeoNavia®, a new innovative pulse biopsy system for ultrasound guided tissue sampling, is currently being introduced to the market. The biopsy system is built on a patented pulse technology, based on research at the Karolinska Institutet in Sweden. NeoNavia has received CE approval and is bing marketed in UK, Germany, and Sweden. The pulse biopsy system has been used for tissue sampling in breast and axilla in over 500 patients. NeoDynamic´s share is listed on Nasdaq First North Growth Market Stockholm (ticker: NEOD). The company’s Certified Adviser is Redeye AB.